Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganetespib (STA-9090) in Metastatic Pancreatic Cancer
NCT01227018Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Dec 2010
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ganetespib in pancreatic adenocarcinoma (PDAC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Disease Control Rate at 8 weeks. Started Dec 2010; status: terminated.
02
Drugs
ganetespib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01227018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01227018.